Clinical infectious diseasesStennis NL, Burzynski JN, Herbert C, et al. Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York City health department clinics. Clin Infect Dis 2016; 62:53-9.Stennis NL, Burzynski JN, Herbert C, Nilsen D, Macaraig M. ...
Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350(20):2060-2067.PubMedGoogle ScholarCrossref 5. Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of ...
A spokesman at the university said: "Although a vaccine for TB was developed 100 years ago, one in three people across the world are thought to be infected with the infectious disease. About 1.7 million die from the bug each year worldwide and 7.3 million people were diagnosed and treated ...
INTRODUCTION: Tuberculosis is a widespread and increasingly important infectious disease. A third of the world-wide population is infected. Every year nin... C Llerena,SE Fadul,MC Garzón,... - 《Biomedica》 被引量: 21发表: 2010年 Management of Tuberculosis in Children and New Treatment Option...
SETTING: Treatment for latent tuberculous infection (LTBI) reduces the risk of tuberculosis (TB) disease. Shorter, rifamycin-containing regimens have been shown to be as effective as 6 months of isoniazid and superior with regard to safety and completion rate. It is unknown whether preventive thera...
Mycobacterium tuberculosis, the cause of Tuberculosis (TB), infects one third of the world’s population and causes substantial mortality worldwide. In its shortest format, treatment of TB requires six months of multidrug therapy with a mixture of broad spectrum and mycobacterial specific antibiotics...
Pic story: doctor dedicated to tuberculosis prevention, treatment in Changsha Xiao Yangbao (1st L) watches his daughters play at home in Changsha, capital of central China's Hunan Province, Aug. 15, 2019. Returning home from hospital, Xiao, as a doctor for infectious disease treatment, ...
Tuberculosis (TB) is an infectious disease requiring adherence to long-term treatment and the tracing of patient's contacts, thus justifying it being a notifiable disease in most countries of the world. This ancient disease continues to be an important public health problem, and for this reason ...
Tuberculosis (TB) is a communicable disease that is a major cause of illness and death worldwide. Prior to the COVID-19 pandemic, TB surpassed human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) as the most common infectious agent-related cause of mortality1. It continues ...
UVBI was developed by Dr Emmet Knott in 1928,2, 3 after Finsen received the Nobel Prize in 1903 for his ultraviolet light therapy of the skin in patients with lupus vulgaris, i.e., tuberculosis of the skin.4, 5 Finsen described the treatment of 804 patients with tuberculosis of the skin...